Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

Next Previous
Trial Profile

An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nedosiran (Primary)
  • Indications Primary hyperoxaluria
  • Focus Therapeutic Use
  • Acronyms PHYOX 3
  • Sponsors Dicerna Pharmaceuticals; Novo Nordisk

Most Recent Events

  • 30 May 2025 Status changed from recruiting to active, no longer recruiting.
  • 02 Oct 2023 According to Novo Nordisk media release, U.S. FDA has approved RivflozaTM for children 9 years of age and older and adults living with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function. This approval is based on interim data of this trial and results of phase 2 PHYOXTM2 trial.
  • 27 Jul 2023 Planned End Date changed from 1 Jul 2027 to 1 Apr 2030.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top